Evidence map›Paper›PMID 32290730›Full record

ArticleChannels (Austin, Tex.)2020

The CaMKII phosphorylation site Thr1604 in the Ca

Jingyuan Li, Siqi Wang, Jie Zhang, Yan Liu, Xi Zheng, Fan Ding, Xuefei Sun, Meimi Zhao, Liying Hao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Channels (Austin, Tex.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jingyuan LiDepartment of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang, China.
Siqi WangDepartment of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang, China.
Jie ZhangDepartment of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang, China.
Yan LiuDepartment of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang, China.
Xi ZhengDepartment of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang, China.
Fan DingDepartment of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang, China.
Xuefei SunDepartment of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang, China.
Meimi ZhaoDepartment of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang, China.
Liying HaoDepartment of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang, China.ORCID 0000-0002-0301-1827
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Residue Thr1604 in the Ca

Indexed as

AnimalsCalcium-Calmodulin-Dependent Protein Kinase Type 2Calcium Channels, L-TypeCardiomegalyCells, CulturedIsoproterenolMaleMyocardiumMyocytes, CardiacPhosphorylationRatsRats, Sprague-DawleyCalcium-Calmodulin-Dependent Protein Kinase Type 2Calcium Channels, L-TypeIsoproterenolL-type calcium channel alpha(1C)CaMKIICaV1.2 channelmyocardial hypertrophyphosphorylationThr1604

Identifiers

PMID32290730
PMCPMC7188351
OpenAlexW3015630598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.